Efficient secretory expression of type III recombinant human collagen with triple-helical structure in Komagataella phaffii

作者：Yaqian Ma, Yang Li, Nan Wang, Chenxiao Han, Qisheng Liu, Liqin Sun, Zhao Ma, Hailing Zhang · 发表于：Applied Microbiology and Biotechnology · 年份：2025 · DOI：10.1007/s00253-025-13566-3 · 被引用次数：4 · 研究领域：Collagen: Extraction and Characterization、Enzyme Production and Characterization、Silk-based biomaterials and applications

Collagen is a major structural component of the extracellular matrix and the most abundant protein in the human body, accounting for nearly one-third of total protein. In recent years, recombinant human collagen (rhCol) has attracted growing attention due to its controllable composition, low immunogenicity, and excellent biocompatibility. Compared to animal-derived collagen, rhCol offers superior batch-to-batch consistency, enhanced solubility, and eliminates the risk of pathogen transmission (Guo et al. 2024 ). It is typically produced by genetically engineering key functional domains of human collagen and has been widely applied in various biomedical fields. Most of the studies cited here focus on rhCol in general, without specifying collagen subtypes (Samantha Lo and Fauzi 2021 ; Kong et al. 2022 ; Wang et al. 2024 , 2025 ; Revert-Ros et al. 2024 ). However, a subset of recent studies has specifically examined recombinant type III collagen (rhCol III) for its therapeutic and regenerative potential (Ye et al. 2024 ; Wang 2021 ; Yang et al. 2021 ; Cao et al. 2024 ). Recent studies have shown that rhCol can promote skin regeneration, inhibit melanin production, and enhance endogenous collagen synthesis. Additionally, it can function as a vehicle (e.g., hydrogels and scaffolds) to deliver drugs or bioactive agents to specific tissues (Huo et al. 2021 ; Zhou et al. 2023 ). In the fields of periodontal and corneal stromal regeneration, rhCol has also demonstrated promising thera...